Grandmasterflash88 Posted - 3 days ago

$NERV Any hope left in this old dogfart?

RollingDollar Posted - 1 week ago

$NERV

frontiere Posted - 3 weeks ago

$NERV Minerva — imminent catalyst but why is NERV not publishing it? No position for me yet , still digging. per 2023 10-K filed 2024-02-23, in 1Q24 expects Ph1b readout MIN-101C18 of concomitant roluperidone w olanzapine in moderate to severe schizophrenia - trial marked as completed 2024-02-12 officially. Source: https://clinicaltrials.gov/study/NCT06107803 Also: - as of 2023-12-31 cash=$41m , Neg EV at ~$18m MCap. - $22.6m S-3 shelf / ATM available as of 2023-12-31 . - last dilution PIPE $20m @ $10 2023-06-28 w Boehringer . - 2024-02-27 received CRL from FDA for Roluperidone for schizophrenia. Many comments from FDA, req new trial & data issues. Will need lots of funding if keep pursuing this direction. Or perhaps will abandon and pivot? 🤔

Grandmasterflash88 Posted - 3 weeks ago

$NERV What are their plan forward after the rejection?. Do they need dilute short term?

Sergioski Posted - 3 weeks ago

$NERV Price seemingly hanging on to hopes that J&J drug Seltorexant gets FDA approval (NERV would stand to receive milestone payments and a royalty if this is the case). This could allow $NERV the capital runway to retool their Roluperidone study with the FDA...my near term sentiment remains negative, would love to hear what others have to say, this board seems to be in the mortuary so I'm not expecting to hear back at this point...

Sergioski Posted - 3 weeks ago

$NERV I was bullish over a year ago. I since backed out because I felt like CEO Luthringer downplayed the FDA's insistence that therapists were unlikely to prescribe roluperidone as a monotherapy in the real world. Dr. Luthringer's approach seemed to be to attempt to change the FDA's mind rather than taking guidance and designing a trial that would show improvement among patients that were on generally accepted treatment protocols. In my view, the FDA was concerned about drug interactivity...Today this still seems to be the case which has me on the bearish side of things. I'm interested what others think

Sergioski Posted - 3 weeks ago

$NERV just wanted to check in and see if Bulls have a compelling thesis here, seems the company does not have a desire to show drug interactivity and was hoping for an approval based sheerly on a monotherapy treatment design. It seems clear the FDA has no appetite to consider monotherapy despite the compelling 64mg dose data...Does $NERV sell to a company with cash to sustainably design a drug interactivity program, do they raise capital, other paths forward, thanks...

RallyRaider Posted - 1 month ago

$NERV NOT what you want to see--- If you have something great, you want to tell the world about it.

RollingDollar Posted - 1 month ago

$NERV

Finnisher2M Posted - 1 month ago

$BIOL I'll keep an eye on this👀 $XELA A total surprise. This seems to be moving upwards as well🤣 $NERV Long position✅ Adding dips $PTPI Number #1 worldwide💎👇 🔥You can look at those charts. I'm more interested in the news that will come next week🔥 "STENDRA may be the first in its class to achieve this marketing status, also establishing company know-how as a proven platform for other prospective prescription therapeutics."

skyrockets_Inc Posted - 1 month ago

$NERV I've been an on and off investor in this one for years. This is not a bash post or a slight in the company in any way. Serious comment. When are they just going to finally announce Strategic Alternatives and either RM or sale the asset (if they can). They need to do it at this point, too many failures in the a row just burning through cash. I'm going to buy back in if it gets close to or sub $2/share.

Finnisher2M Posted - 1 month ago

$NERV I'm taking a long position here📈✅💰💰💰

ElijahJobs Posted - 1 month ago

$ACAD Shows how tough it is to meet the primary ends of the clinical trials for negative symptoms of schizophrenia... $NERV should not feel bad about its recent CRL. $BMY could be the only one with a viable candidate for the symptoms now that it recently acquired $KRTX. JMO

MountainMan33 Posted - 1 month ago

$NERV he said

Sergioski Posted - 1 month ago

$BCDA Wow, this wolf of Wall Street guy comes out of NOWHERE after positive news drops. Shorts are paying the mills to protect their evermore precarious position...Wolf go short $NERV, it's a no- brainier, BCDA will eat you alive

Sergioski Posted - 1 month ago

$BCDA Bears on here looking to short something should check out $NERV. Their Roluperidone candidate just failed FDA review. They have been pushing this medication as a treatment for negative symptoms of schizophrenia for about 20 years, they are a one trick pony and the pony is not performing. They are down big, but NASDAQ CM compliance will be coming unless they are able to pivot which is unlikely, given their track record

debbiekatz Posted - 1 month ago

$nerv looks cheap here at 2.78

RollingDollar Posted - 1 month ago

$NERV

RollingDollar Posted - 1 month ago

$NERV

Aigner_Andreas Posted - 1 month ago

#DeathCross $NERV at 2.56 R65 HiLo 8% T1Y 12 buy 2.2 DIV N/A #Minerva Ne #stocks #trading #finance #market

JebusMatoi Posted - 1 month ago

$NERV Tf happened

Dozz Posted - 1 month ago

$NERV I might consider to buy after 50-60% decrease following the rs. Possibly around oct or nov 24.

feebles12 Posted - 1 month ago

$NERV will this do the same thing it's done for the past two years and work it's way up and fall, work up, and fall? Or is this the end?

feebles12 Posted - 1 month ago

$NERV i

_www_larval_com_ Posted - 1 month ago

$NERV just slipped -5% lower to -8% (~509Kv) in the last few minutes, follow for more volatility.

skyrockets_Inc Posted - 1 month ago

$NERV I'll buy sub $2

stocktwitsoptions Posted - 1 month ago

$NERV

Profitfire Posted - 1 month ago

@barrettsanders @IronPatriot1001 @MountainMan33 good Morning mountain… are you in a hurry ?😂 around 1.80 is a open down gap so I am sure this will be closed in the near therm! It’s often with biotechnology stocks with huge gaps they are open… I invested here a long long time ago… but is was for few dollar the stock price… after more than 100% profit I left the company and now I saw the massig drop and I will do my dd to probably invest again in $NERV So I still waiting for a entry and with patients i will be in again 🌚 Technically analysis tell me atm just wait and my target will filled some day 🙌📈

MountainMan33 Posted - 02/29/24

$NERV to the iron one

IronPatriot1001 Posted - 02/29/24

@MountainMan33 brother, I work in a heavily regulated industry. The last fight your business wants to pick is against the government. Regulators are all the same. They will cause retribution for even the smallest things Despite the medicine being supported via the most recent trials, $NERV was basically battling the FDA continuously. They hate that shit. The total patient size for Roluperidone in the US is rather small, with many doctors afraid of being sued for switching patients to an unknown (even if effective) mono treatment. To top off that sweet slice of pie, their runway is only going to last them mere months. Their competition Acadia Pharmaceuticals is bringing Nuplazid to market as well. If all of this didn't ring the village alarm bells in your head, not sure what to tell you. I avoided that catastrophic cliff of a share price drop. Hope you did the same.